CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jaguar Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jaguar Health Inc
200 PINE STREET SUITE 400
Phone: (415) 371-8300p:415 371-8300 SAN FRANCISCO, CA  94104  United States Ticker: JAGXJAGX

Business Summary
Jaguar Health, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. It operates through two segments: human health and animal health. Human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. Its subsidiary includes Napo Pharmaceuticals, Inc., which focuses on developing and commercializing plant-based human pharmaceuticals.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board James J.Bochnowski 79 12/1/2018 2/1/2014
President, Chief Executive Officer, Director Lisa A.Conte 63 6/1/2013 6/1/2013
Chief Financial Officer Carol R.Lizak 59 4/6/2021 8/13/2019
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Napo Pharmaceuticals, Inc. 185 Berry Street San Francisco CA United States

Business Names
Business Name
Dragon SPAC SpA
JAGX
Napo EU SpA
Napo Pharmaceuticals, Inc.
Napo Therapeutics S.p.A.

General Information
Number of Employees: 60 (As of 12/31/2022)
Outstanding Shares: 233,423,917 (As of 3/18/2024)
Shareholders: 18
Stock Exchange: NASD
Federal Tax Id: 462956775
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024